COMPANY ANALYSIS REPORT

Submitted By M.KUMARAN II MBA 10520

Submitted To Dr.M.D.MANOGARAN Ph.D Director RLIMS

COMPANY PROFILE

Khwaja Abdul Hamied, the founder of Cipla, was born on October 31, 1898. In 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs. Cipla was officially opened on September 22, 1937 when the first products were ready for the market. July 4, 1939 was a red-letter day for Cipla, when the Father of the Nation, Mahatma Gandhi, honoured the factory with a visit.

BOARD OF DIRECTORS
Founder Dr. K.A. Hamied (1898-1972) Chairman & Managing Director Dr. Y.K. Hamied Joint Managing Directors Mr. M.K. Hamied Mr. Amar Lulla Non-Executive Directors Mr. V.C. Kotwal Dr. H.R. Manchanda Mr. S.A.A. Pinto Mr. M.R. Raghavan Mr. Ramesh Shroff Mr. Pankaj Patel

GLOBAL PRESENCE
Exports for the financial year ended March 31, 2010 amounted to more than Rs. 29,000 million. Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. Cipla also offers technology for products and processes.

Technical know-how/fees received during the year 2009-10 amounted to about Rs. 1500 million. Cipla's manufacturing facilities have been approved by various international regulatory authorities including: Food and Drug Administration (FDA), USA Medicines and Healthcare products Regulatory Agency (MHRA), UK Therapeutic Goods Administration (TGA), Australia Medicines Control Council (MCC), South Africa National Institute of Pharmacy (NIP), Hungary Pharamaceutical Inspection Convention (PIC), Germany World Health Organisation (WHO) Department of Health, Canada State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil . Cipla products are bought by over 180 countries

VISION
Cipla started with a vision to build a healthy India. And along the way realised, that in our own small way, we could contribute to making the world a healthier place. Well continue to bring a smile on as many faces as we can to heal the world as much as we can.

MISSION
The mission of caring for life, which continues to this day and God willing it will continue in the future.

POLICIES
1. Ethical conduct 2. Conflict of interest 3. Transparency 4. Legal compliance 5. Rightful use of companys assets 6. Cost consciousness 7. Confidential information 8. Relationships with Suppliers and Customers 9. Interaction with Media 10. Safety and Environment

DEPARTMENTS
Child Care

Cough, Colds & Flu Eye Care Food Supplements Foot Care Hair Care Health Drinks Life Style Products Low - Calorie Sweetener Nutraceuticals & Tonics Oral Hygiene Others Pain Care Probiotics / Indigestion Skin Care Sports Care / Muscle Building Vitamins And Minerals

COMPETITORS
RANBAXY NICHOLAS PIRAMAL SUN PHARMA NOVARTIS PFIZER REDDY LABS

SWOT
STRENGTHS : -Exports to over 175 countries that contribute 54% of the total turnover. -Market leader in key therapeutic areas such as respiratory care and anti-viral. -Company has an extensive distribution network. -Cipla has 18 brands that features among the top 300 brands. -Large basket of around 1500 formulations. -One of the countrys best R&D Process. WEAKNESS: -Domestic growth was steady at 10 per cent.

-Growth in formulation exports was affected due to various factors including nonavailability of important raw materials, lower tender business in anti-retroviral. OPPORTUNITIES:

- 46 ANDAs pending for approval in US. - Plans of launching bio-similar, particularly relating to the oncology, anti-asthmatic and anti-arthritis categories - Around 10% contribution to the revenue from the Indore SEZ to start coming in from FY2013E. - 56 Inhalers products are at different stages of approvals. THREATS:

- Some pending legal cases on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. - Sensitive to fluctuations in foreign currency exchange rates.

FINANCIAL STATUS:
During the year under review, the Companys total income from operations increased by 12 per cent. Domestic turnover rose by 12 per cent while export income went upby 16 per cent. Profi t after tax for the year was `960 crorecompared to `1081 crore last year, excluding the one-timesale of the I-pill brand last year. On the occasion of its 75th anniversary, Cipla declared a special interim dividend of 80 paise per equity share (face value of `2 each) in August 2010 amounting to `74.90 crore (inclusive of dividend tax). The Directors recommend a fi nal dividend of `2 per share on 80,29,21,357 equity shares of `2 each for the year 2010-11 amounting to `160.58 crore. The total dividend payout for the year 2010-11 inclusive of dividend tax would aggregate to `261.53 crore.

AWARDS AND ACHIVEMENTS:

1935 Dr K A Hamied sets up "The Chemical, Industrial and Pharmaceutical Laboratories Ltd." in a rented bungalow, at Bombay Central. 1941 As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort.

1952 Sets up first research division for attaining self-sufficiency in technological development. 1960 Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. 1968 Cipla manufactures ampicillin for the first time in the country. 1972 Starts Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. 1976 Cipla launches medicinal aerosols for asthma. 1980 Wins Chemexcil Award for Excellence for exports. 1982 Fourth factory begins operations at Patalganga, Maharashtra. 1984 Develops anti-cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune. Wins Sir P C Ray Award for developing inhouse technology for indigenous manufacture of a number of basic drugs. 1985 US FDA approves Cipla's bulk drug manufacturing facilities. 1988 Cipla wins National Award for Successful Commercialisation of Publicly Funded R&D. 1991 Lauches etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology. The company pioneers the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad. 1994 Cipla's fifth factory begins commercial production at Kurkumbh, Maharashtra. 1997 Launches transparent Rotahaler, the world's first such dry powder inhaler device now patented by Cipla in India and abroad. The palliative cancer care centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune.

1998 Launches lamivudine, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched). 1999 Launches Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. 2000 Cipla became the first company, outside the USA and Europe to launch CFC -free inhalers ten years before the deadline to phase out use of CFC in medicinal products. 2002 Four state-of-the-art manufacturing facilities set up in Goa in a record time of less than twelve months. 2003 Launches TIOVA (Tiotropium bromide), a novel inhaled, long-acting anticholinergic bronchodilator that is employed as a once-daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). Commissioned second phase of manufacturing operations at Goa. 2005 Set-up state-of-the-art facility for manufacture of formulations at Baddi, Himachal Pradesh. 2007 Set-up state-of-the-art facility for manufacture of formulations at Sikkim. 2010 Set up state-of-the-art facility for manufacture of formulations at Indore